相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
Daniel Zingg et al.
NATURE COMMUNICATIONS (2015)
The Risk of Melanoma in Airline Pilots and Cabin Crew A Meta-analysis
Martina Sanlorenzo et al.
JAMA DERMATOLOGY (2015)
5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies
Jonathan J. Lee et al.
MODERN PATHOLOGY (2015)
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers
Michael Christoph Haffner et al.
Oncotarget (2015)
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
S. Turajlic et al.
ANNALS OF ONCOLOGY (2014)
Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology
C. Swanton et al.
ANNALS OF ONCOLOGY (2014)
Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged
Paul B. Chapman et al.
CANCER CELL (2014)
Chromosome 10, Frequently Lost in Human Melanoma, Encodes Multiple Tumor-Suppressive Functions
Lawrence N. Kwong et al.
CANCER RESEARCH (2014)
Identification of a melanoma susceptibility locus and somatic mutation in TET2
Fengju Song et al.
CARCINOGENESIS (2014)
Understanding the Biology of Melanoma and Therapeutic Implications
Ryan J. Sullivan et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
J. S. Ross et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi
Ryuhei Uchiyama et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2014)
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Klaus G. Griewank et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Up Close and Personal: The Challenges of Precision Medicine in Melanoma
Keiran S. M. Smalley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Melanoma epigenetics: novel mechanisms, markers, and medicines
Jonathan J. Lee et al.
LABORATORY INVESTIGATION (2014)
Environmental exposures, epigenetic changes and the risk of lupus
E. C. Somers et al.
LUPUS (2014)
Genetic landscape of esophageal squamous cell carcinoma
Yi-Bo Gao et al.
NATURE GENETICS (2014)
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
Jianxin Shi et al.
NATURE GENETICS (2014)
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma
William R. Jeck et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Clonal Architectures and Driver Mutations in Metastatic Melanomas
Li Ding et al.
PLOS ONE (2014)
The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
Jennifer A. Lo et al.
SCIENCE (2014)
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes
Robert Huether et al.
NATURE COMMUNICATIONS (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
Stefan Groeschel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Howard L. Kaufman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
MAP kinase signaling and inhibition in melanoma
R. J. Sullivan et al.
ONCOGENE (2013)
EVI1 Inhibits Apoptosis Induced by Antileukemic Drugs via Upregulation of CDKN1A/p21/WAF in Human Myeloid Cells
Anna Rommer et al.
PLOS ONE (2013)
EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation
Emilie A. Bard-Chapeau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Franklin W. Huang et al.
SCIENCE (2013)
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Bozic et al.
ELIFE (2013)
Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis
Keisuke Kataoka et al.
CANCER SCIENCE (2012)
Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma
Christine Guo Lian et al.
CELL (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
DNA methylation: TET proteins-guardians of CpG islands?
Kristine Williams et al.
EMBO REPORTS (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
5-Methylcytosine and 5-Hydroxymethylcytosine Spatiotemporal Profiles in the Mouse Zygote
Juliette Salvaing et al.
PLOS ONE (2012)
Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways
Changcun Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Demystifying DNA Demethylation
Christopher S. Nabel et al.
SCIENCE (2011)
Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
Yu-Fei He et al.
SCIENCE (2011)
Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine
Shinsuke Ito et al.
SCIENCE (2011)
Mutator transposon activation after UV-B involves chromatin remodeling
Julia I. Qüesta et al.
Epigenetics (2010)
Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism
Zachary J. Reitman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lighting a path to pigmentation: mechanisms of MITF induction by UV
Jue J. Liu et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High EVI1 levels predict adverse outcome in acute myeloid leukemia:: prevalence of EVI1 overexpression. and chromosome 3q26 abnormalities underestimated
Sanne Lugthart et al.
BLOOD (2008)
UV and pigmentation: molecular mechanisms and social controversies
Thanh-Nga T. Tran et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Methylation of lysine 4 on histone H3: Intricacy of writing and reading a single epigenetic mark
Alexander J. Ruthenburg et al.
MOLECULAR CELL (2007)
Malignant melanoma: genetics and therapeutics in the genomic era
Lynda Chin et al.
GENES & DEVELOPMENT (2006)
Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer
BC Bastian
ONCOGENE (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
A natural history of melanomas and dysplastic nevi - An atlas of lesions in melanoma-prone families
MA Tucker et al.
CANCER (2002)
分享论文
